Compounds > ampicillin
Page last updated: 2024-08-17

ampicillin and oritavancin

ampicillin has been researched along with oritavancin in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's1 (20.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arhin, FF; Draghi, DC; Moeck, G; Parr, TR; Pillar, CM; Sahm, DF1
Andrews, J; Fraise, AP; Wise, R1
Baltch, AL; Bopp, LH; Ritz, WJ; Smith, RP1
Aeschlimann, JR; Hershberger, E; Moldovan, T; Rybak, MJ1
Aitken, SL; Dahesh, S; Nizet, V; Sakoulas, G; Tran, TT; Wong, B1

Other Studies

5 other study(ies) available for ampicillin and oritavancin

ArticleYear
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:11

    Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus faecium; Glycopeptides; Gram-Positive Bacteria; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus

2009
Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
    The Journal of antimicrobial chemotherapy, 1997, Volume: 40, Issue:3

    Topics: Ampicillin; Anti-Bacterial Agents; Enterococcus; Enterococcus faecalis; Enterococcus faecium; Gentamicins; Glycopeptides; Gram-Positive Bacteria; Lipoglycopeptides; Microbial Sensitivity Tests; Teicoplanin; Vancomycin

1997
Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
    Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:10

    Topics: Ampicillin; Anti-Bacterial Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Enterococcus faecium; Glycopeptides; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Vancomycin

1998
Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by
    Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:3

    Topics: Ampicillin; Anti-Bacterial Agents; Antibiotics, Antitubercular; Drug Therapy, Combination; Fluoroquinolones; Gentamicins; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Naphthyridines; Rifampin; Staphylococcus aureus; Sulbactam; Teicoplanin; Time Factors; Vancomycin; Virginiamycin

1999
Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:7

    Topics: Ampicillin; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Drug Synergism; Enterococcus faecium; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Male; Microbial Sensitivity Tests; Middle Aged; Osteomyelitis; Vancomycin; Vancomycin-Resistant Enterococci

2019